N
ALLO icon

Nuveen’s Allogene Therapeutics ALLO Stock Holding History

Nuveen’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.65M Buy
2,315,092
+2,043,085
+751% +$4.1M ﹤0.01% 1829
2025
Q4 		$373K Hold
272,007
– – ﹤0.01% 2982
2025
Q3 		$337K Hold
272,007
– – ﹤0.01% 3027
2025
Q2 		$307K Buy
272,007
+56,641
+26% +$75.3K ﹤0.01% 3043
2025
Q1 		$13.3M Sell
215,366
-85,505
-28% -$161K ﹤0.01% 1377
2024
Q4 		$641K Buy
300,871
+46,632
+18% +$115K ﹤0.01% 2893
2024
Q3 		$712K Buy
254,239
+15,170
+6% +$40.4K ﹤0.01% 2891
2024
Q2 		$557K Sell
239,069
-63,186
-21% -$186K ﹤0.01% 2950
2024
Q1 		$1.35M Sell
302,255
-55,303
-15% -$231K ﹤0.01% 2575
2023
Q4 		$1.15M Sell
357,558
-2,643
-0.7% -$7.5K ﹤0.01% 2672
2023
Q3 		$1.14M Buy
360,201
+23,337
+7% +$102K ﹤0.01% 2524
2023
Q2 		$1.67M Buy
336,864
+63,186
+23% +$342K ﹤0.01% 2431
2023
Q1 		$1.35M Buy
273,678
+56,329
+26% +$361K ﹤0.01% 2493
2022
Q4 		$1.37M Sell
217,349
-129,820
-37% -$1.2M ﹤0.01% 2548
2022
Q3 		$3.75M Sell
347,169
-227,183
-40% -$3.09M ﹤0.01% 2060
2022
Q2 		$6.55M Sell
574,352
-105,469
-16% -$936K ﹤0.01% 1774
2022
Q1 		$6.45M Buy
679,821
+338,767
+99% +$3.53M ﹤0.01% 1921
2021
Q4 		$5.09M Sell
341,054
-104,476
-23% -$1.84M ﹤0.01% 2098
2021
Q3 		$11.4M Sell
445,530
-128,074
-22% -$3.04M ﹤0.01% 1686
2021
Q2 		$15M Buy
573,604
+345,555
+152% +$9.85M ﹤0.01% 1596
2021
Q1 		$8.05M Sell
228,049
-7,316
-3% -$247K ﹤0.01% 1915
2020
Q4 		$5.94M Sell
235,365
-118,130
-33% -$3.85M ﹤0.01% 1980
2020
Q3 		$13.3M Sell
353,495
-10,374
-3% -$391K 0.01% 1327
2020
Q2 		$15.6M Buy
363,869
+211,485
+139% +$7.65M 0.01% 1196
2020
Q1 		$2.96M Buy
152,384
+1,589
+1% +$37.8K ﹤0.01% 1991
2019
Q4 		$3.92M Sell
150,795
-422,232
-74% -$11.6M ﹤0.01% 2119
2019
Q3 		$15.6M Buy
573,027
+15,595
+3% +$444K 0.01% 1289
2019
Q2 		$15M Buy
+557,432
New +$15.5M 0.01% 1339

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen's ALLO Position: Q1 2026 in Review

Nuveen increased its Allogene Therapeutics (ALLO) stake by 751% in Q1 2026, buying an estimated $4.1M and bringing the position to 2,315,092 shares worth $5.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1829.

Nuveen first reported a position in ALLO in Q2 2019 and has held it in 28 quarters since. The position peaked at $15.6M in Q3 2019. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Nuveen held 2,315,092 shares of Allogene Therapeutics worth $5.65M as of Q1 2026.
  • Nuveen bought 2,043,085 Allogene Therapeutics shares in Q1 2026, an estimated $4.1M.
  • Allogene Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1829 holding.
  • Nuveen first reported a position in Allogene Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • Nuveen's Allogene Therapeutics position peaked at $15.6M in Q3 2019.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.